TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26695176

Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle program consisting of four to five individual consultations over one year
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 366
Study: 23037617

Group type: COMPARATOR
Intervention: Strength and endurance (SE) group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strength, endurance, and maximal‐effort cycling (SEC) group
Number of subjects: 20
Study: 21245882

Group type: EXPERIMENTAL
Intervention: Calcium fortified laddoo containing 405 mg calcium per day and a monthly vitamin D supplement of 30,000 IU
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-fortified laddoo containing 156 mg of indigenous calcium and a monthly vitamin D supplement of 30,000 IU
Number of subjects: 60
Study: 18802818

Group type: EXPERIMENTAL
Intervention: Sonification pulse rate set to 60 pulses per minute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Variable sonification pulse rates and sensor reliability
Number of subjects: 0
Study: 16409195

Group type: EXPERIMENTAL
Intervention: House dust mite immunotherapy with Alutard SQ (Dermatophagoides pteronyssinus extract) for 52 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 12627930

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 80 mg administered after consumption of a standardized continental breakfast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Testosterone undecanoate 80 mg administered during a fasting period
Number of subjects: 16
Study: 10846306

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy for adolescents (CBGT‐A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 35
Study: 9113218

Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 106

Group type: COMPARATOR
Intervention: Moderate drinking goal
Number of subjects: 106
Study: 31184506

Group type: EXPERIMENTAL
Intervention: Keratography (K5M, Oculus, Germany)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Swept-source OCT (Casia SS-1000, Tomey Corp, Japan)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluorescein instillation (moistened fluorescein strip)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conjunctival touch (inferior bulbar or inferior palpebral)
Number of subjects: 41
Study: 28198032

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.5 mg/kg, IV, three times a day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.5 mg/kg, IV, three times a day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Maropitant (1 mg/kg, SC, once a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 23266232

Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA) followed by stenting
Number of subjects: 240

Group type: COMPARATOR
Intervention: Stenting without RA (standard therapy group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 21494052

Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa Patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 75
Study: 18222382

Group type: EXPERIMENTAL
Intervention: Greater social network size
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Smaller social network size
Number of subjects: 605
Study: 16459509

Group type: EXPERIMENTAL
Intervention: Teaching health education combined with leaflet and drama methods
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Leaflet-only group
Number of subjects: 1005
Study: 12638098

Group type: EXPERIMENTAL
Intervention: Active left limb movement (button push; n=3)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Passive left limb movement with functional electric stimulation (FES; n=8)
Number of subjects: 9
Study: 10229295

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrene (triamterene 50 mg with hydrochlorothiazide 25 mg) daily
Number of subjects: 20
Study: 10158542

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Non-hysterectomy treatment
Number of subjects: 200000
Study: 1878335

Group type: EXPERIMENTAL
Intervention: Nicardipine 40 mg slow-release b.i.d.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg slow-release b.i.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6130842

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg/night
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31091527

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 110
Study: 27545509

Group type: EXPERIMENTAL
Intervention: Omega 3/6 capsules (three capsules twice daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 27533157

Group type: EXPERIMENTAL
Intervention: Abaloparatide, 80 μg
Number of subjects: 2463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: Teriparatide, 20 μg
Number of subjects: 2463
Study: 24710994

Group type: EXPERIMENTAL
Intervention: Individually tailored interactive multimedia computer program (IMCP)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Attention control (sleep hygiene video)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Targeted depression public service announcement (PSA) video
Number of subjects: 867
Study: 23113962

Group type: EXPERIMENTAL
Intervention: CT slice interval of 1.25 mm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CT slice interval of 2.5 mm
Number of subjects: 30

Group type: COMPARATOR
Intervention: CT slice interval of 5 mm
Number of subjects: 30
Study: 19452124

Group type: EXPERIMENTAL
Intervention: AS extract (3 g per day) plus calcium (500 mg per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calcium (500 mg per day)
Number of subjects: 81
Study: 17465977

Group type: COMPARATOR
Intervention: Alfentanil 0.5 mg intravenously
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Propofol 0.7 mg/kg intravenously
Number of subjects: 82
Study: 15143082

Group type: EXPERIMENTAL
Intervention: VAC therapy (vincristine, dactinomycin, and cyclophosphamide)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: VAC therapy with concomitant abdominal radiotherapy
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (VAC alternating with vincristine, topotecan, and cyclophosphamide)
Number of subjects: 339
Study: 11166149

Group type: EXPERIMENTAL
Intervention: Psychological Distress Inventory and Hospital Anxiety and Depression Scale administered before and during chemotherapy, and at the first follow‐up visit.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Logistic regression including clinical and demographic variables (age, psychiatric history).
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Two questionnaires (Psychological Distress Inventory and Hospital Anxiety and Depression Scale).
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Three predictive models developed for each evaluation point including age, psychiatric history, and psychological distress.
Number of subjects: 132
Study: 9749820

Group type: EXPERIMENTAL
Intervention: Self-directed method (experimental group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Faculty-assisted method (control group)
Number of subjects: 98
Study: 7868849

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 3349432

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Combination of tumor burden, histologic subtype, and sex
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Tumor burden and age
Number of subjects: 290
Study: 30676196

Group type: EXPERIMENTAL
Intervention: 35 g of whey protein combined with resistance training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo combined with resistance training
Number of subjects: 30
Study: 28632587

Group type: EXPERIMENTAL
Intervention: Computer-navigated knee arthroplasty
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional knee arthroplasty
Number of subjects: 162
Study: 25921846

Group type: EXPERIMENTAL
Intervention: Plant sterols during the four-year follow-up
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Lathosterol levels
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Interaction of rs4299376 and study group
Number of subjects: 340
Study: 23032071

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 21775748

Group type: EXPERIMENTAL
Intervention: Project Dulce peer intervention
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 207
Study: 19835725

Group type: EXPERIMENTAL
Intervention: Gel alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Gel plus SLS
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 260
Study: 16522914

Group type: EXPERIMENTAL
Intervention: 1500 mg Ca/d (as calcium carbonate)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 12536052

Group type: EXPERIMENTAL
Intervention: Valproate sodium infused at 3.0 mg/kg/min
Number of subjects: 112

Group type: COMPARATOR
Intervention: Valproate sodium infused at 1.5 mg/kg/min
Number of subjects: 112
Study: 11114135

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pump-prime-only aprotinin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 8657237

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: CABG (diabetic subgroup)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: PTCA (diabetic subgroup)
Number of subjects: 1829
Study: 2058821

Group type: EXPERIMENTAL
Intervention: Computer-controlled infusion of propofol and ketamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simple administration regimen of propofol and ketamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 6439019

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG‐TTS), 5 mg/24 hr
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31244356

Group type: EXPERIMENTAL
Intervention: Methotrexate + IFX therapy
Number of subjects: 128
Study: 31842529

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 90
Study: 28088187

Group type: COMPARATOR
Intervention: Oral ergocalciferol plus placebo (n = 36)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol plus calcitriol (n = 32)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 25996459

Group type: EXPERIMENTAL
Intervention: Lung age intervention (lung age determination, education, and smoking cessation advice)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual smoking education (control group)
Number of subjects: 108
Study: 23575309

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT) for 21 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 38
Study: 21102493

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (60 mg) before surgery
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intravenous normal saline (control group)
Number of subjects: 67
Study: 19579920

Group type: EXPERIMENTAL
Intervention: 200 mcg misoprostol placed in posterior fornix of case group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo tablet in control group
Number of subjects: 66
Study: 16907704

Group type: EXPERIMENTAL
Intervention: Common single nucleotide polymorphisms (SNPs) in 9 innate immunity genes (CARD15, IRAK1, IRAK4, LBP, LY86, MEFV, TLR2, TLR4, NFKB1)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Non-synonymous SNPs in TLR4 and CARD15
Number of subjects: 717
Study: 14967547

Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation training in addition to work therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Work therapy only
Number of subjects: 94
Study: 11438853

Group type: EXPERIMENTAL
Intervention: Primary caregivers of spinal cord injury survivors
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 50
Study: 9924327

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol combination solution administered twice daily (Cosopt)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Dorzolamide solution twice daily plus timolol maleate solution twice daily (concomitant)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Both groups (combination and concomitant)
Number of subjects: 299
Study: 7816415

Group type: EXPERIMENTAL
Intervention: Intraoperative administration of mitomycin C (4% solution, applied for 3 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgical excision only (control group)
Number of subjects: 30
Study: 3290427

Group type: EXPERIMENTAL
Intervention: Sanguinarine-containing dentifrice (750 mcg/g)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo dentifrice (similar composition without sanguinarine)
Number of subjects: 120
Study: 30627178

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 28679366

Group type: EXPERIMENTAL
Intervention: Small scaled homelike SCU
Number of subjects: 145

Group type: COMPARATOR
Intervention: Regular SCU
Number of subjects: 145
Study: 25794212

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (bolus 1.5 mg/kg at induction, then infusion at 2 mg/kg/hr, up to 2 hours after surgery)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 23462886

Group type: EXPERIMENTAL
Intervention: MSDC-0160 (50, 100, or 150 mg)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: MSDC-0160 (higher doses)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: MSDC-0160
Number of subjects: 258

Group type: COMPARATOR
Intervention: pioglitazone (45 mg)
Number of subjects: 258

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study: 21672053

Group type: EXPERIMENTAL
Intervention: High dose CYT003-QbG10
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 18266655

Group type: EXPERIMENTAL
Intervention: Excite DSC/Variolink II without silanization (Group A1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Excite DSC/Variolink II with silanization (Group A2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scotchbond MPP/RelyX ARC without silanization (Group B1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scotchbond MPP/RelyX ARC with silanization (Group B2)
Number of subjects: 40
Study: 17458083

Group type: EXPERIMENTAL
Intervention: Corsodyl gel + surgical dressing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scaling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corsodyl rinse
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corsodyl gel
Number of subjects: 40
Study: 12776809

Group type: EXPERIMENTAL
Intervention: SB-LOT (30 mg coumarin and 180 mg troxerutin t.i.d.)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: SB-LOT
Number of subjects: 231
Study: 10867429

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acidulated phosphate fluoride (APF) group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dicalcium phosphate dihydrate (DCPD) - APF group
Number of subjects: 18
Study: 9413801

Group type: EXPERIMENTAL
Intervention: Personal book intervention (N = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Personal book + three video-feedback sessions (N = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (N = 30)
Number of subjects: 90
Study: 1590289

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 23
Study: 7267676

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31438960

Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) implementation in community mental health clinics
Number of subjects: 5

Group type: COMPARATOR
Intervention: EHRs in different stages of development
Number of subjects: 5

Group type: COMPARATOR
Intervention: Qualitative data from focus groups and interviews
Number of subjects: 5
Study: 28122335

Group type: EXPERIMENTAL
Intervention: PS detection in patient plasma using a highly stringent ELISA
Number of subjects: 44
Study: 25573500

Group type: EXPERIMENTAL
Intervention: Motion-mode (MM) echography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anatomical motion-mode (AMM) echography
Number of subjects: 50
Study: 24229770

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 50
Study: 21397519

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture
Number of subjects: 6
Study: 19637354

Group type: EXPERIMENTAL
Intervention: Dual-screen (annual chest X-ray and 4-monthly sputum cytology)
Number of subjects: 20426

Group type: COMPARATOR
Intervention: X-ray only arm
Number of subjects: 20426
Study: 17377048

Group type: EXPERIMENTAL
Intervention: Reconstruction increment of 3.0 mm (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reconstruction increment of 1.5 mm (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reconstruction increment of 3.0 mm (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reconstruction increment of 1.5 mm (Group B)
Number of subjects: 40
Study: 16982395

Group type: EXPERIMENTAL
Intervention: Using a condom
Number of subjects: 418

Group type: COMPARATOR
Intervention: Not using a condom
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Having sex
Number of subjects: 418
Study: 12960598

Group type: EXPERIMENTAL
Intervention: Incremental nitroglycerin infusion (NTG+Inf)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Resting TF imaging without NTG+Inf
Number of subjects: 50
Study: 10522281

Group type: EXPERIMENTAL
Intervention: Practiced without visual restrictions before transferring to full vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practiced with visual restrictions before transferring to full vision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7567309

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg once daily for 10 days)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Penicillin V (25 mg/kg/day in 3 divided doses for 10 days)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Ceftibuten and Penicillin V
Number of subjects: 426
Study: 2174492

Group type: EXPERIMENTAL
Intervention: 2 mg of delta-9-tetrahydrocannabinol (THC) followed by 3.2 mg flumazenil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.5 mg of delta-9-tetrahydrocannabinol (THC) followed by 3.2 mg flumazenil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 mg of delta-9-tetrahydrocannabinol (THC) followed by 6.4 mg flumazenil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo after THC
Number of subjects: 15
Study: 7019406

Group type: EXPERIMENTAL
Intervention: Early closure of the PDA using indomethacin (mean = 48.8 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional medical management (intervention only after cardiopulmonary decompensation, mean = 167.4 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Early closure of the PDA using indomethacin
Number of subjects: 24
Study: 30632922

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 167
Study: 30773300

Group type: EXPERIMENTAL
Intervention: Caffeinated group (150 mL decaffeinated coffee with additional 200 mg caffeine)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Decaffeinated group (150 mL decaffeinated coffee)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Caffeinated group with CYP1A2 rs762551 CC genotype and daily caffeine consumption ≤90 mg/day
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Caffeinated group with CYP1A2 rs762551 AA/CA genotype and daily caffeine consumption ≤90 mg/day
Number of subjects: 201
Study: 28511035

Group type: EXPERIMENTAL
Intervention: Speech condition with social threat induction (giving an impromptu speech)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No-speech condition without social threat induction
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Speech condition with social threat induction
Number of subjects: 91
Study: 26209926

Group type: EXPERIMENTAL
Intervention: GHB (20mg/kg)
Number of subjects: 16
Study: 23819228

Group type: EXPERIMENTAL
Intervention: Moxibustion at Baihui (GV 20)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 120
Study: 21519745

Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus (30 mg/kg/day)
Number of subjects: 56
Study: 18358691

Group type: EXPERIMENTAL
Intervention: Nurse-assisted symptom control intervention
Number of subjects: 214